Table 2.
Ad26/MVA | Ad26/Ad26 + gp140 | Placebo | All subjects | |
---|---|---|---|---|
Analysis set: full analysis set | 10 | 9 | 6 | 25 |
Age, years | ||||
N | 10 | 9 | 6 | 25 |
Mean (SD) | 42.1 (10.25) | 37.9 (9.71) | 44.8 (11.39) | 41.2 (10.28) |
Median (min; max) | 44.5 (28;58) | 39.0 (29;59) | 47.5 (30;56) | 41.0 (28;59) |
Sex | ||||
N | 10 | 9 | 6 | 25 |
Female | 0 | 1 (11.1%) | 2 (33.3%) | 3 (12.0%) |
Male | 10 (100.0%) | 8 (88.9%) | 4 (66.7%) | 22 (88.0%) |
Race | ||||
N | 9 | 7 | 6 | 22 |
Asian | 1 (11.1%) | 0 | 0 | 1 (4.5%) |
Black or African American | 0 | 0 | 1 (16.7%) | 1 (4.5%) |
Native Hawaiian or Other Pacific Islander | 0 | 1 (14.3%) | 0 | 1 (4.5%) |
White | 8 (88.9%) | 6 (85.7%) | 5 (83.3%) | 19 (86.4%) |
Ethnicity | ||||
N | 9 | 9 | 6 | 24 |
Hispanic or Latino | 4 (44.4%) | 3 (33.3%) | 2 (33.3%) | 9 (37.5%) |
Not Hispanic or Latino | 5 (55.6%) | 6 (66.7%) | 4 (66.7%) | 15 (62.5%) |
Weight, kg | ||||
N | 10 | 9 | 6 | 25 |
Mean (SD) | 78.4 (8.06) | 82.0 (17.76) | 100.6 (19.00) | 85.0 (16.95) |
Median (min; max) | 75.9 (68.3;93.3) | 80.6 (62.2;121.2) | 99.9 (74.8;128.4) | 82.1 (62.2;128.4) |
Height, cm | ||||
N | 10 | 9 | 6 | 25 |
Mean (SD) | 175.7 (4.83) | 175.6 (6.96) | 169.4 (9.85) | 174.1 (7.24) |
Median (min; max) | 175.4 (169.0;185.8) | 178.3 (165.4;184.1) | 172.0 (152.0;179.7) | 175.2 (152.0;185.8) |
HIV RNA, copies/mL | ||||
N | 10 | 9 | 6 | 25 |
Mean (SD) | 21.4 (8.88) | 21.2 (8.03) | 15.7 (8.16) | 20.0 (8.43) |
Median (min; max) | 19.0 (11;31) | 19.0 (11;31) | 11.0 (11;31) | 19.0 (11;31) |
CD4 Cell Count, /uL | ||||
N | 10 | 9 | 6 | 25 |
Mean (SD) | 695.1 (345.56) | 672.7 (131.54) | 775.3 (152.18) | 706.3 (238.83) |
Median (min; max) | 566.5 (385;1377) | 646.0 (521;895) | 773.0 (521;950) | 654.0 (385;1377) |
Duration on current ART | ||||
N | 10 | 9 | 6 | 25 |
Mean (SD) | 1.573 (0.9509) | 4.593 (6.1450) | 1.244 (0.6480) | 2.581 (3.9245) |
Median (min; max) | 1.235 (0.71; 3.25) | 2.519 (0.82; 20.36) | 0.976 (0.68; 2.22) | 1.251 (0.68; 20.36) |